Table 2 Serum lipid changes by antiviral regimen.

From: Serum lipid profile in HCV patients treated with direct-acting antivirals: a systematic review and meta-analysis

Subgroup by DAA regimen

Studies (N) and references

4 Weeks MD (95% CI)

mg/dl

Studies (N) and references

12 Weeks MD (95% CI)

mg/dl

Studies (N) and references

SVR12 MD (95% CI)

mg/dl

Total cholesterol

DCV/ASV

42,12,17,18

+ 11.05 (7.36–14.74)

p < 0.001

I2 = 24.1% (p = 0.267)

42,12,17,23

+ 17.25 (6.09–28.42)

p = 0.002

I2 = 75.9% (p = 0.006)

32,12,17

+ 24.33 (18.74–29.91)

p < 0.001

I2 = 0% (p = 0.939)

SOF/LDV

32,12,18

+ 31.79 (23.35–40.22)

p < 0.001

I2 = 51.3% (p = 0.128)

32,12,21

+ 26.98 (19.46–34.49)

p < 0.001

I2 = 28.5% (p = 0.247)

32,12,21

+ 17.29 (17.14–17.44)

p < 0.001

I2 = 0% (p = 0.549)

LDL cholesterol

DCV/ASV

42,12,17,18

+ 9.68 (5.39–13.97)

p < 0.001

I2 = 46.7% (p = 0.131)

32,12,17

+ 6.57 (1.95–11.18)

p = 0.005

I2 = 0% (p = 0.688)

42,12,17,23

+ 20.92 (16.31–25.53)

p < 0.001

I2 = 0% (p = 0.708)

SOF/LDV

32,12,18

+ 25.52 (19.33–31.71)

p < 0.001

I2 = 35.3% (p = 0.213)

22,12

+ 21.57 (16.11–27.04)

p < 0.001

I2 = 0% (p = 0.793)

22,12

+ 9.28 (4.34–14.21)

p < 0.001

I2 = 0% (p = 0.586)

HDL cholesterol

DCV/ASV

32,12,17

− 3.10 (− 7.294 to + 1.094)

p = 0.630

I2 = 64.4% (p = 0.06)

32,12,17

+ 2.34 (− 1.611 to 6.31)

p = 0.245

I2 = 53.2% (p = 0.118)

42,12,17,23

+ 5.08 (2.44–7.71)

p < 0.001

I2 = 0% (p = 0.628)

SOF/LDV

212

+ 5.72 (2.99–8.44)

p < 0.001

I2 = 0% (p = 0.944)

22,12

+ 7.51 (3.90–11.13)

p < 0.001

I2 = 14.9% (p = 0.27)

22,12

+ 3.08 (− 0.82 to + 7.00)

p = 0.122

I2 = 30% (p = 0.632)

  1. DCV/ASV daclatasvir/asunaprevir, SOF/LDV sofosbuvir/ledipasvir, MD mean difference, SVR12 sustained virological response at 12 week.
Back to article page